Japanese drugmaker Kyorin Pharmaceutical (TYO: 4569) has entered into a licensee agreement with Bayer (BAYN: DE) for the novel obstructive sleep apnea (OSA) treatment BAY2925976 and its backup compound discovered by the German pharma major.
Kyorin have obtained the exclusive worldwide rights to manufacture, develop, and commercialize BAY2925976 and its backup compound, in return for which it will make an upfront payment of 15 million euros ($15.8 million) to Bayer along with milestone payments of up to 70 million euros based on development progress.
Additionally, royalties based on net sales and commercialization milestone payments will be provided to Bayer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze